Valproate Sodium Injection
Brand names: Valproate Sodium
Category: Neurology
FDA status: Current · Last FDA update: Sep 18, 2026 · First posted: Dec 30, 2020 (in shortage 5 years 9 months) · 2 manufacturers, 2 listed presentations
As of Sep 18, 2026, the FDA lists Valproate Sodium Injection as currently in shortage. Of 2 manufacturer presentations, 2 Available.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05) NDC 63323-494-05 |
Fresenius Kabi USA, LLC | Available | Checkwholesalers for inventory |
| Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10) NDC 0143-9785-10 |
Hikma Pharmaceuticals USA, Inc. | Available | Additional lots will be available. Product will be made available as it is released. |
Related medications in shortage
Other Neurology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Valproate Sodium Injection (FDA data as of Sep 18, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Valproate Sodium Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/valproate-sodium-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).